Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?

Citation
Inzucchi SE, Fitchett D, Jurišić‐Eržen D, et al. Diabetes Obes Metab 2020;22:631–9.